The Week in Review: IPOs, Patents, Investment Funds and More

Four China life science companies have completed very successful IPOs and three more expect to do so soon, dispelling the notion that IPOs are dead; the Third Amendment to China’s Patent Law took effect with the goal of improving IP protection in China; China Construction Bank announced a 2.6 billion RMB ($380 million) private equity fund for healthcare companies; Shenzhen will invest 500 million RMB ($73.5 million) annually in healthcare companies for seven years; Zhangjiang Hi-Tech Park will invest 48 million RMB ($7 million) to buy a .4% stake in Shandong Buchang Pharma; China's Anti-Monopoly Bureau has given its okay to the merger between Pfizer and Wyeth; Eli Lilly plans to double its workforce inside of China this year; Sinovac Biotech (北京科兴生物制品有限公司) announced a second large H1N1 flu vaccine order; Kyorin Pharma licensed the ex-Japan Asian rights of an OAB drug to Eisai; and Heath Robotics signed a five-year agreement with SINOPHARM for its IV robots. More details... Stock Symbols: (HK: 0939) (NYSE: PFE) (NYSE: WYE) (NYSE: LLY) (NYSE: SVA) (TSE: 4523)